Terms: = Thyroid cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Treatment
32 results:
1. Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants.
Ahmed S; Wedekind MF; Del Rivero J; Raygada M; Lockridge R; Glod JW; Flowers C; Thomas BJ; Bernstein DB; Kapustina OB; Jain A; Miettinen M; Raffeld M; Xi L; Tyagi M; Kim J; Aldape K; Malayeri AA; Kaplan RN; Allen T; Vivelo CA; Sandler AB; Widemann BC; Reilly KM;
Cancer Res Commun; 2023 Dec; 3(12):2468-2482. PubMed ID: 37966258
[TBL] [Abstract] [Full Text] [Related]
2. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
3. Curcumin induces mitophagy by promoting mitochondrial succinate dehydrogenase activity and sensitizes human papillary thyroid carcinoma BCPAP cells to radioiodine treatment.
Zhang L; Qiu L; Xu S; Cheng X; Wu J; Wang Y; Gao W; Bao J; Yu H
Toxicol In Vitro; 2023 Dec; 93():105669. PubMed ID: 37634662
[TBL] [Abstract] [Full Text] [Related]
4. Papillary thyroid cancer immune phenotypes via tumor-infiltrating lymphocyte spatial analysis.
Nam M; Yang W; Kim HS; Park J; Park G; Kim S; Song S; Ock CY; Wang VG; Chuang JH; Chae YK
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37279258
[TBL] [Abstract] [Full Text] [Related]
5. RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway.
Feng Z; Ke S; Wang C; Lu S; Xu Y; Yu H; Li Z; Yin B; Li X; Hua Y; Qian B; Bai M; Fu Y; Zhang Y; Wu Y; Ma Y
Oncogene; 2023 Jun; 42(24):2017-2030. PubMed ID: 37142680
[TBL] [Abstract] [Full Text] [Related]
6. CircRNF10-DHX15 interaction suppressed breast cancer progression by antagonizing DHX15-NF-κB p65 positive feedback loop.
Zheng W; Wang X; Yu Y; Ji C; Fang L
Cell Mol Biol Lett; 2023 Apr; 28(1):34. PubMed ID: 37101128
[TBL] [Abstract] [Full Text] [Related]
7. PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis.
Liu A; Yu C; Qiu C; Wu Q; Huang C; Li X; She X; Wan K; Liu L; Li M; Wang Z; Chen Y; Hu F; Song D; Li K; Zhao C; Deng H; Sun X; Xu F; Lai S; Luo X; Hu J; Wang G
Oncogene; 2023 May; 42(19):1572-1584. PubMed ID: 36991117
[TBL] [Abstract] [Full Text] [Related]
8. TRIB3 Interacts with STAT3 to Promote cancer Angiogenesis.
Chen QZ; Chen Y; Li X; Liu H; Sun XL
Curr Med Sci; 2022 Oct; 42(5):932-940. PubMed ID: 36245025
[TBL] [Abstract] [Full Text] [Related]
9. Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary thyroid cancer.
Zhang HM; Li ZY; Dai ZT; Wang J; Li LW; Zong QB; Li JP; Zhang TC; Liao XH
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233293
[TBL] [Abstract] [Full Text] [Related]
10. Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway.
Luo X; Wang J; Lu J; Wang X; Miao Y; Li Q; Li X; Wang L
Biomed Res Int; 2022; 2022():1874550. PubMed ID: 35757470
[TBL] [Abstract] [Full Text] [Related]
11. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway.
Zhang W; Ruan X; Li Y; Zhi J; Hu L; Hou X; Shi X; Wang X; Wang J; Ma W; Gu P; Zheng X; Gao M
Theranostics; 2022; 12(4):1500-1517. PubMed ID: 35198054
[No Abstract] [Full Text] [Related]
12. SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination.
Dong S; Pan J; Shen YB; Zhu LX; Chen L; Zhu F; Li H; Shen HX; Xia Q; Wu YJ; Xie XJ
Endocr Relat Cancer; 2022 Mar; 29(4):175-189. PubMed ID: 35073278
[TBL] [Abstract] [Full Text] [Related]
13. Cdc25A inhibits autophagy-mediated ferroptosis by upregulating ErbB2 through PKM2 dephosphorylation in cervical cancer cells.
Wang C; Zeng J; Li LJ; Xue M; He SL
Cell Death Dis; 2021 Nov; 12(11):1055. PubMed ID: 34743185
[TBL] [Abstract] [Full Text] [Related]
14. [Endocrine and neuroendocrine tumors].
Riss P; Scheuba K; Strobel O
Chirurg; 2021 Nov; 92(11):996-1002. PubMed ID: 34618164
[TBL] [Abstract] [Full Text] [Related]
15. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
de la Fouchardière C; Godbert Y; Dalban C; Illouz F; Wassermann J; Do Cao C; Bardet S; Zerdoud S; Chougnet CN; Zalzali M; Benisvy D; Niccoli P; Digue L; Lamartina L; Schwartz P; Borson Chazot F; Gautier J; Pérol D; Leboulleux S;
Eur J Cancer; 2021 Nov; 157():153-164. PubMed ID: 34509954
[TBL] [Abstract] [Full Text] [Related]
16. Achalasia and acromegaly: Co-incidence of these diseases or a new syndrome?
Dolina J; Kunovsky L; Kroupa R; Stary K; Jabandziev P; Nesporova T; Maca K; Andrasina T; Marek F; Kala Z; Vaculova J; Said D; Zapletalova M; Lochman J; Palova Noskova H; Slaby O; Izakovicova Holla L; Borilova Linhartova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):228-235. PubMed ID: 34282806
[TBL] [Abstract] [Full Text] [Related]
17. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
[TBL] [Abstract] [Full Text] [Related]
18. Carotid Body Tumor - radiological imaging and genetic assessment.
Berger G; Łukasiewicz A; Grinevych V; Tarasów E
Pol Przegl Chir; 2020 Nov; 92(6):39-44. PubMed ID: 33408267
[TBL] [Abstract] [Full Text] [Related]
19. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.
Modak S; Zanzonico P; Grkovski M; Slotkin EK; Carrasquillo JA; Lyashchenko SK; Lewis JS; Cheung IY; Heaton T; LaQuaglia MP; Cheung NV; Pandit-Taskar N
J Clin Oncol; 2020 Dec; 38(36):4283-4291. PubMed ID: 33119478
[TBL] [Abstract] [Full Text] [Related]
20. Experimental studies of boron neutron capture therapy (BNCT) using histone deacetylase inhibitor (HDACI) sodium butyrate, as a complementary drug for the treatment of poorly differentiated thyroid cancer (PDTC).
Perona M; Majdalani ME; Rodríguez C; Nievas S; Carpano M; Rossini A; Longhino JM; Cabrini R; Pisarev MA; Juvenal GJ; Dagrosa MA
Appl Radiat Isot; 2020 Oct; 164():109297. PubMed ID: 32768887
[TBL] [Abstract] [Full Text] [Related]
[Next]
